DNA sequence preferences at sites cleaved by human DNA topoisomerase II in response to novel quinolone derivatives.
We have examined the DNA cleavage site specificity of human type II DNA topoisomerase in the presence of each of five novel quinolone derivatives. Each quinolone derivative inhibited the human enzyme, inducing double-strand breaks with a four-base stagger. Break sites generated in response to each derivative had a predominance of C in the 3'-terminal position. Consensus sequences derived for cleavage sites induced by each derivative were strikingly similar, not only at the 3'-terminal position, but also at additional positions on either side of the broken phosphodiester bond. Analysis of these consensus sequences yielded information about possible interactions of specific substituents on the quinolone derivatives with DNA and/or topoisomerase. Comparison of the quinolone-based consensus sequences with those derived for cleavage sites generated by the human type II topoisomerase in the presence of either m-AMSA or VM-26, or in the absence of drug, provided compelling evidence that DNA cleavage sites include two domains: one which interacts with drug and a second, larger domain which interacts with topoisomerase.
Huff
A C
AC
Sterling Winthrop Pharmaceuticals Research Division, Sterling Winthrop, Inc., Collegeville, PA 19426, USA.
Robinson
R G
RG
Evans
A C
AC
Selander
K N
KN
Wentland
M P
MP
Rake
J B
JB
Coughlin
S A
SA
D000677:Amsacrine / Q000494:pharmacology; D001483:Base Sequence; D004247:DNA / Q000378:metabolism*; D004250:DNA Topoisomerases, Type II / Q000378:metabolism*; D006367:HeLa Cells; D006801:Humans; D006868:Hydrolysis; D008969:Molecular Sequence Data; D015363:Quinolones / Q000494:pharmacology*; D013379:Substrate Specificity; D013713:Teniposide / Q000494:pharmacology; D059005:Topoisomerase II Inhibitors
D015363:Quinolones; D059005:Topoisomerase II Inhibitors; D000677:Amsacrine; D004247:DNA; D013713:Teniposide; D004250:DNA Topoisomerases, Type II